Svmuu News: Revolut CEO Nik Storonsky stated that the company's public listing is still at least two years away, potentially delayed until 2028 at the earliest, with no immediate IPO plans. He pointed out that Revolut is currently focusing on expanding in the US market, including applying for a banking license to gain access to the Federal Reserve's payment system and expand its lending and credit card business. Meanwhile, the company has already obtained a full banking license in the UK.
Prior to going public, Revolut will continue to provide liquidity for employees and early investors through regular secondary market financing. The company's latest valuation is approximately $75 billion, with 2025 revenue around $6 billion and net profit increasing 57% year-on-year to approximately $2.3 billion. Its user base has exceeded 68 million. (Crypto Briefing)
Revolut CEO: IPO Potentially Delayed Until 2028, Actively Advancing US Banking License Application
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
5
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
6
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
7
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
8
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
9
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
-
10
Analysis: Vanguard Small-Cap Growth ETF (VBK) up 21% YTD 2026, Outperforming Large-Cap Growth ETF (VONG) at 0.3% YTD
Markets Today
Recommended Reading







